Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease.

BACKGROUND The long-term treatment outcomes of Mycobacterium avium complex (MAC) lung disease (LD) have not been adequately evaluated. OBJECTIVE We evaluated the determinants of microbiological recurrence after successful treatment for MAC LD. DESIGN The medical records of 295 MAC LD patients treated with combination chemotherapy from 2004 to 2013 were reviewed. The clinical data, microbiological study results and chest computerised tomography findings were collected for each patient. RESULTS Ninety-one patients who maintained negative sputum conversion during treatment and had a minimum 10-month follow-up period after treatment were included. The median duration of follow-up was 25 months. Seventy-one (78.0%) patients remained microbiologically disease-free, while 20 (22.0%) had microbiological recurrence after successful treatment. Age, sex and body mass index were not associated with microbiological recurrence. Longer intervals between initial diagnosis and administration of medication (P = 0.024), increased number of involved lobes (P = 0.033) and failure of sputum conversion within 6 months of initiating treatment (P = 0.017) were significantly associated with microbiological recurrence. CONCLUSION Microbiological recurrence after successful anti-MAC chemotherapy was associated with the time interval between initial diagnosis and administration of medication, number of lobes involved and time to sputum conversion during treatment.

[1]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[2]  J. Igual,et al.  Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  R. Wallace,,et al.  Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. , 1994, American journal of respiratory and critical care medicine.

[4]  A. Niimi,et al.  Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[5]  T. Kanauchi,et al.  Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[6]  Y. Yamamoto,et al.  Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  H. Yoon,et al.  Risk factors for deterioration of nodular bronchiectatic Mycobacterium avium complex lung disease. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  B. Parker,et al.  Recent experience in the epidemiology of disease caused by atypical mycobacteria. , 1981, Reviews of infectious diseases.

[9]  R. Wallace,,et al.  Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. , 2002, The Journal of infectious diseases.

[10]  R. Arbeit,et al.  Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS , 1994, The Lancet.

[11]  William Girard,et al.  Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.

[12]  Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  J. Yim,et al.  Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  S. Field,et al.  Mycobacterium avium complex pulmonary disease in patients without HIV infection. , 2004, Chest.

[15]  D. Snider,et al.  The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. , 1987, The American review of respiratory disease.

[16]  B. Dautzenberg,et al.  Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. , 1995, Chest.

[17]  D. Peterson,et al.  Infection with Mycobacterium avium complex in patients without predisposing conditions. , 1989, The New England journal of medicine.

[18]  S. Field,et al.  Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. , 2003, Chest.

[19]  Youngchul Kim,et al.  The Impact of the 2007 ATS/IDSA Diagnostic Criteria for Nontuberculous Mycobacterial Disease on the Diagnosis of Nontuberculous Mycobacterial Lung Disease , 2010, Respiration.

[20]  R. Wallace,,et al.  Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. , 1996, American journal of respiratory and critical care medicine.

[21]  H. McAdams,et al.  The many faces of pulmonary nontuberculous mycobacterial infection. , 2007, AJR. American journal of roentgenology.

[22]  R. Wallace,,et al.  Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. , 1998, American journal of respiratory and critical care medicine.

[23]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.